Current Report Filing (8-k)
May 20 2020 - 12:03PM
Edgar (US Regulatory)
9U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
8-K
Current Report Pursuant to Section 13 or
15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 14, 2020
Cannapharmarx,
Inc.
(Exact name of small business issuer as
specified in its charter)
Delaware
|
000-27055
|
24-4635140
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer ID No.)
|
3600
888-3rd Street SW
Calgary, Alberta, Canada T2P5C5
(Address of principal executive offices)
(949) 652-6838
(Issuer’s Telephone Number)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Not Applicable
|
Not Applicable
|
Not Applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2
of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure
|
Attached is a copy of a shareholder letter
issued by CannaPharmaRX, Inc. (the “Company”) a copy of which is attached as Exhibit 99.7 and is hereby incorporated.
The Company intends to post this letter to its investor relations section of its website and to distribute to its shareholders.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(c) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 20, 2020
|
CANNAPHARMARX, INC.
|
|
|
|
By:
|
/s/ Dominic Colvin
|
|
|
Dominic Colvin
Chief Executive Officer
|
Cannapharmarx (PK) (USOTC:CPMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannapharmarx (PK) (USOTC:CPMD)
Historical Stock Chart
From Sep 2023 to Sep 2024